Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)

多维单细胞方法探讨 HIV-1 整合与非艾滋病定义癌症的关联(生物样本/生物队列)

基本信息

  • 批准号:
    10619156
  • 负责人:
  • 金额:
    $ 25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Current treatments for HIV-1 infection include suppressive anti-retroviral therapy (ART), which curtails active viral replication to nearly undetectable levels. However, ART fails to cure HIV-1 infection because the virus persists indefinitely in a latent state. While people living with HIV-1 (PLWH) live longer, they are subject to secondary long-term consequences due to the ART regime itself and the presence of integrated proviruses throughout the human genome. Whereas ART facilitated a decrease in the incidence of AIDS defining cancers, an increased incidence of non-AIDS defining cancers (NADC), such as T and B cell lymphomas, has been well documented in the clinics. Despite previous controversies regarding the role of HIV-1 integration site and cancer prevalence, the clinical association between HIV-1 integration in defined sites and NADC prevalence remains largely unexplored. Given these previous findings and gaps in knowledge, the central hypothesis of this proposal is that HIV-1 integration into or nearby select human genes alters their expression thereby causing NADC. Specifically, HIV-1 integration might disrupt the normal expression of HIV-1 Associated GEnes (HAGEs) causing upregulation of proto-oncogenes, downregulation of tumor suppressors and/or altering RNA splicing patterns, consequently rewiring gene expression programs producing abnormal CD4+ T and B cell expansion and/or behaviors leading to NADC. The major goal of this proposal is to interrogate whether select HIV-1 integration sites are associated with increased incidence of NADC in PLWH under suppressive therapy and to predict associated biomarkers. To start accomplishing this goal, we will deploy a multidimensional approach to concurrently profile HIV-1 integration sites and human transcriptomes at the single cell level in a unique cohort available through the AIDS and Cancer Specimen Resource (ACSR). This will be the first ever approach that can simultaneously interrogate the relationship between HIV-1 integration sites and human transcriptomes at the single cell level in participants biospecimens. We already have on hand an impressive molecular and genomic toolset that will be strategic for accomplishing the Specific Aims of this proposal. These include: 1) To deploy a multidimensional single cell approach to simultaneously collect HIV-1 integration sites and human transcriptomes in ACSR participants biospecimens (Aim 1), and 2) to combine the generated datasets to define participants HIV-1 integration-induced biomarkers associated with NADC (Aim 2). Collectively, these studies will reveal viral integration sites over-represented in PLWH with NADC, link individual viral integration sites to altered human gene expression potentially explaining the onset of NADC, and categorize biomarkers linked to select HIV-1 integration events for diagnostic and prognostic outcomes. Future studies using this knowledge will functionally define specific HIV-1 integration events as NADC drivers and help devise alternative therapeutic opportunities.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carlos L Arteaga其他文献

Methods of Evaluating EGFR Expression The causal role of high expression of HER 2 in cancer
评估 EGFR 表达的方法 HER 2 高表达在癌症中的因果作用
  • DOI:
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Carlos L Arteaga
  • 通讯作者:
    Carlos L Arteaga
HER3 and mutant EGFR meet MET
HER3 与突变型 EGFR 与 MET 相遇
  • DOI:
    10.1038/nm0607-675
  • 发表时间:
    2007-06-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Carlos L Arteaga
  • 通讯作者:
    Carlos L Arteaga
Selecting the right patient for tumor therapy
为肿瘤治疗选择合适的患者
  • DOI:
    10.1038/nm0604-577
  • 发表时间:
    2004-06-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Carlos L Arteaga
  • 通讯作者:
    Carlos L Arteaga

Carlos L Arteaga的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carlos L Arteaga', 18)}}的其他基金

Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
新辅助来那替尼治疗 I-III 期 HER2 突变小叶乳腺癌
  • 批准号:
    10660734
  • 财政年份:
    2023
  • 资助金额:
    $ 25万
  • 项目类别:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
HER2 突变在乳腺癌进展和靶向治疗反应中的作用
  • 批准号:
    9759820
  • 财政年份:
    2018
  • 资助金额:
    $ 25万
  • 项目类别:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
HER2 突变在乳腺癌进展和靶向治疗反应中的作用
  • 批准号:
    10214565
  • 财政年份:
    2018
  • 资助金额:
    $ 25万
  • 项目类别:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
HER2 突变在乳腺癌进展和靶向治疗反应中的作用
  • 批准号:
    10458531
  • 财政年份:
    2018
  • 资助金额:
    $ 25万
  • 项目类别:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
HER2 突变在乳腺癌进展和靶向治疗反应中的作用
  • 批准号:
    9614453
  • 财政年份:
    2018
  • 资助金额:
    $ 25万
  • 项目类别:
Admin/Outreach Core
管理/外展核心
  • 批准号:
    8947587
  • 财政年份:
    2014
  • 资助金额:
    $ 25万
  • 项目类别:
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br
抑制 P13 激酶作为消除 Br 抗雌激素耐药性的策略
  • 批准号:
    8764757
  • 财政年份:
    2014
  • 资助金额:
    $ 25万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    8764765
  • 财政年份:
    2014
  • 资助金额:
    $ 25万
  • 项目类别:
Career Development Program
职业发展计划
  • 批准号:
    8764766
  • 财政年份:
    2014
  • 资助金额:
    $ 25万
  • 项目类别:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
UT 西南医学中心西蒙斯综合癌症中心
  • 批准号:
    10693201
  • 财政年份:
    2010
  • 资助金额:
    $ 25万
  • 项目类别:

相似海外基金

Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
  • 批准号:
    24K19213
  • 财政年份:
    2024
  • 资助金额:
    $ 25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
  • 批准号:
    23K15982
  • 财政年份:
    2023
  • 资助金额:
    $ 25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
  • 批准号:
    10606730
  • 财政年份:
    2023
  • 资助金额:
    $ 25万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 25万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10987699
  • 财政年份:
    2023
  • 资助金额:
    $ 25万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10541285
  • 财政年份:
    2022
  • 资助金额:
    $ 25万
  • 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10540952
  • 财政年份:
    2022
  • 资助金额:
    $ 25万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10703446
  • 财政年份:
    2022
  • 资助金额:
    $ 25万
  • 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
  • 批准号:
    22K08497
  • 财政年份:
    2022
  • 资助金额:
    $ 25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10707312
  • 财政年份:
    2022
  • 资助金额:
    $ 25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了